European Archives - Page 514 of 1056 - European Medical Journal

Late-Breaking Abstracts: Health Status Benefits of Mavacamten in Obstructive Hypertrophic Cardiomyopathy and the Modifying Effect of Ejection Fraction on the Therapeutic Benefit of Omecamtiv Mecarbil in Heart Failure

Two late-breaking abstracts at the American College of Cardiology’s virtual meeting ACC.21 delved further into the data of two pivotal trials

EMJ 6.2 Feature Image

Understanding the Impact of Non-Dystrophic Myotonia on Patients and Caregivers: Results from a Burden of Disease Healthcare Survey

Non-dystrophic myotonias (NDM) manifest as delayed muscle relaxation (myotonia) leading to muscle stiffness that may diminish or worsen…

Prevalence of Scoliosis in Hypermobile Ehlers-Danlos Syndrome

The main purpose of this study was to evaluate the prevalence, form, and severity of scoliosis in a population of adults meeting the 2017 criteria for hypermobile Ehlers-Danlos syndrome (hEDS).

Pre-transplant Determinants of Outcome in Patients with Myeloma

Multiple myeloma is a malignant neoplasm arising from clonal proliferation of plasma cells in the bone marrow…

New Therapeutic Approaches for Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is a life-threatening, multifactorial haematological neoplasm characterised by the accumulation of transformed immature myeloid progenitors…

Prevalence of Thromboembolic Complications in COVID-19 Infection: A Systematic Review and Meta-Analysis

This study aims to evaluate the prevalence of thromboembolic complications in patients with COVID-19 from March until May 2020.

3D Bone Marrow Model Helps Predict Treatment Response

3D Bone Marrow Model Helps Predict Treatment Response

Predicting individual patient response, as well as progressing understanding of new therapies in development, may be improved by the use of a newly developed 3D bone marrow model.

First Effective Treatment of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia

First Effective Treatment of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia

Balancing risk of adverse reactions against the protection of effective vaccination is a hotly debated topic in the current phase of the global response to the COVID-19 pandemic. Rare blood clot reactions have been of particular concern, and a recently published case report shares the first successful treatment of a vaccine-induced thrombosis reaction.

Liver transplant patients with HBV-related hepatocellular carcinoma

Prof. Patrizia Burra (Italy) and Prof. Ramazan Idilman (Turkey) are sharing their experience with and knowledge about HBV-related liver transplant patients with hepatocellular carcinoma including epidemiology, risk factors for HBV recurrence and current therapy.

Talking to Lorena Kuri

Lorena Kuri, Director of Clinical Trial Diversity Strategy, BMS, discusses how to address underrepresentation in clinical trials.